

# Cell wall inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/CFD891CED7DEN.html>

Date: January 2022

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: CFD891CED7DEN

## Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Cell wall inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Cell wall inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Cell wall inhibitors Understanding

#### Cell wall inhibitors: Overview

Cell wall biosynthesis inhibitors (CBIs) have historically been one of the most effective classes of antibiotics. They are the most extensively used class of antibiotics and their importance is exemplified by the  $\beta$ -lactams and glycopeptide antibiotics. They control Gram-negative and Gram-positive bacterial infection by inhibition of cell wall synthesis and have been used for many decades.

$\beta$ -Lactam antibiotics: They are a broad class of antibiotics that inhibit cell wall synthesis, consisting of all antibiotic agents that contain a  $\beta$ -lactam nucleus in their molecular structures. Some commonly used  $\beta$ -Lactam antibiotics include penicillins, ciclosporins, monobactams, and carbapenems. They are bactericidal

and act by inhibiting the synthesis of peptidoglycan layers in the bacterial cell wall.

**Glycopeptide antibiotics:** They are composed of glycosylated cyclic or polycyclic nonribosomal peptides. Some important glycopeptide antibiotics include vancomycin, teicoplanin, telavancin, bleomycin, and ramoplanin. They inhibit the synthesis of cell walls in susceptible microbes by inhibiting peptidoglycan synthesis.

Although  $\beta$ -lactam antibiotics and glycopeptide antibiotics can treat bacterial infections by inhibiting cell wall biosynthesis, incorrect or excessive use of antibiotics in recent years has increased antibiotic resistance, resulting in less effective treatments than before. The use of bacterial cell wall biosynthesis inhibitors continues to be an effective way to combat bacterial infections.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cell wall inhibitors R&D. The therapies under development are focused on novel approaches for Cell wall inhibitors.

## Cell wall inhibitors Emerging Drugs Chapters

This segment of the Cell wall inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Cell wall inhibitors Emerging Drugs

### CONTEPO: Nabriva Therapeutics

CONTEPO (previously referred to as ZTI-01 and ZOLYD) is an investigational, first-in-class epoxide antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR strains that threaten hospitalized patients.

The FDA has granted CONTEPO Qualified Infectious Disease Product (QIDP) and Fast Track designations for: Complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), hospital-acquired bacterial pneumonia (HABP) / Ventilator-associated bacterial pneumonia (VABP), acute bacterial skin and skin structure infections (ABSSSI). It is currently in preregistration phase of development and is being developed by Nabriva Therapeutics.

#### Tebipenem pivoxil: Spero Therapeutics

Tebipenem HBr, an oral carbapenem that completed a pivotal Phase 3 clinical trial, ADAPT-PO, for the treatment of complicated urinary tract infections and acute pyelonephritis. If approved, tebipenem HBr will be a novel oral formulation of tebipenem, a carbapenem-class antibiotic marketed in Japan since 2009 for specific pediatric infections.

It is currently in phase III stage of development is being developed by Spero Therapeutics.

Further product details are provided in the report.....

#### Cell wall inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Cell wall inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players working on Cell wall inhibitors

There are approx. 30+ key companies which are developing the Cell wall inhibitors. The companies which have their Cell wall inhibitors drug candidates in the most advanced stage, i.e. Preregistration include, Nabriva Therapeutics.

#### Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Cell wall inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cell wall inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cell wall inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cell wall inhibitors drugs.

Cell wall inhibitors Report Insights

Cell wall inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Cell wall inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Scenario and Emerging Therapies:

How many companies are developing Cell wall inhibitors drugs?

How many Cell wall inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Cell wall inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cell wall inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Cell wall inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Recce Pharmaceuticals

Spero Therapeutics

Nabriva Therapeutics

Karveel Pharmaceuticals

Seachaid Pharmaceuticals

### Key Products

RECCE-327

RECCE-111

Tebipenem pivoxil

CONTEPO

SNP021062

SP1001

SP-2078

## Contents

- Introduction
- Executive Summary
- Cell wall inhibitors: Overview
  - Structure
  - Mechanism of Action
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Cell wall inhibitors– DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
  - Cell wall inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value
- Trends
- Cell wall inhibitors Collaboration Deals
  - Company-Company Collaborations (Licensing / Partnering) Analysis
  - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
  - Comparative Analysis
- Tebipenem pivoxil: Spero Therapeutics
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
  - Comparative Analysis
- Drug Name: Company Name
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
  - Comparative Analysis



Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

Comparative Analysis

RECCE-111: Recce Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Cell wall inhibitors Key Companies

Cell wall inhibitors Key Products

Cell wall inhibitors- Unmet Needs

Cell wall inhibitors- Market Drivers and Barriers

Cell wall inhibitors- Future Perspectives and Conclusion

Cell wall inhibitors Analyst Views

Cell wall inhibitors Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Cell wall inhibitors
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Cell wall inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Cell wall inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/CFD891CED7DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CFD891CED7DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970